Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma
Alberto Broniscer, Sharyn D Baker, Cynthia Wetmore, Atmaram S Pai Panandiker, Jie Huang, Andrew M Davidoff, Arzu Onar-Thomas, John C Panetta, Thomas K Chin, Thomas E Merchant, Justin N Baker, Sue C Kaste, Amar Gajjar, Clinton F Stewart, Alberto Broniscer, Sharyn D Baker, Cynthia Wetmore, Atmaram S Pai Panandiker, Jie Huang, Andrew M Davidoff, Arzu Onar-Thomas, John C Panetta, Thomas K Chin, Thomas E Merchant, Justin N Baker, Sue C Kaste, Amar Gajjar, Clinton F Stewart
Abstract
Purpose: Testing of promising drug combinations is crucial in the treatment of diffuse intrinsic pontine glioma (DIPG). As the VEGF and platelet-derived growth factor (PDGF) pathways are critical in gliomas, we evaluated the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of vandetanib, a VEGFR-2 inhibitor, combined with dasatinib, a potent PDGFR inhibitor, during and after radiotherapy in children with newly diagnosed DIPG.
Experimental design: Dasatinib was started concurrently with radiotherapy. Vandetanib was started 8 days later. We tested increasing doses of vandetanib (65 and 85 mg/m(2) once daily) and dasatinib (65 and 85 mg/m(2) twice daily). Dose-limiting toxicities were evaluated during the first 6 weeks of therapy. Plasma pharmacokinetics was obtained on days 8 and 42 ± 3 in all patients and concomitantly with cerebrospinal fluid (CSF) when possible. Inhibition of targets of dasatinib in peripheral blood mononuclear cells (PBMC) was evaluated.
Results: Twenty-five patients were treated. Treatment was well tolerated. The median duration of treatment was 184 days. Diarrhea was the most significant toxicity. Three patients experienced substantial myelosuppression. The steady-state plasma pharmacokinetics of vandetanib was comparable with previous studies. Although the plasma exposure to dasatinib decreased from days 8 to 42, it remained similar to adult studies. CSF to plasma exposure of vandetanib and dasatinib were approximately 2% in 2 patients. Phosphorylated 70S6K decreased during therapy in PBMCs.
Conclusions: The MTD of vandetanib and dasatinib in combination was 65 mg/m(2) for each drug. Other studies are underway to test dasatinib and other PDGFR inhibitors alone or in combination for this deadly cancer.
Conflict of interest statement
Conflict of interest: AstraZeneca partially funded this study and also provided one of the study drugs.
©2013 AACR
Figures
Source: PubMed